XBiotech Inc (NASDAQ:XBIT) — Market Cap & Net Worth
Market Cap & Net Worth: XBiotech Inc (XBIT)
XBiotech Inc (NASDAQ:XBIT) has a market capitalization of $67.99 Million ($67.99 Million) as of August 3, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #20627 globally and #4612 in its home market, demonstrating a -2.19% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying XBiotech Inc's stock price $2.23 by its total outstanding shares 30487731 (30.49 Million). See XBiotech Inc capex to cash flow ratio to understand how much of operating cash flow is reinvested back into capital assets.
XBiotech Inc Market Cap History: 2015 to 2026
XBiotech Inc's market capitalization history from 2015 to 2026. Data shows change from $285.55 Million to $67.99 Million (-14.52% CAGR).
Index Memberships
XBiotech Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.46 Trillion | 0.00% | #585 of 976 |
|
NASDAQ Composite
IXIC
|
$40.26 Trillion | 0.00% | #1987 of 3165 |
Weight: XBiotech Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
XBiotech Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how XBiotech Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
406.50x
XBiotech Inc's market cap is 406.50 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2019 | $490.33 Million | $12.68 Million | $668.63 Million | 38.67x | 0.73x |
| 2020 | $411.12 Million | $44.00 Million | -$11.22 Million | 9.34x | N/A |
| 2021 | $339.33 Million | $18.39 Million | -$17.41 Million | 18.45x | N/A |
| 2022 | $107.01 Million | $4.01 Million | -$32.90 Million | 26.69x | N/A |
| 2023 | $121.95 Million | $300.00K | -$24.56 Million | 406.50x | N/A |
Competitor Companies of XBIT by Market Capitalization
Companies near XBiotech Inc in the global market cap rankings as of August 3, 2026.
Key companies related to XBiotech Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #220 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #424 globally with a market cap of $64.60 Billion USD.
- Argen-X (BR:ARGX): Ranked #543 globally with a market cap of $49.55 Billion USD ( €42.38 Billion EUR).
- UCB SA (BR:UCB): Ranked #563 globally with a market cap of $47.34 Billion USD ( €40.49 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #220 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $477.10 |
| #424 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $64.60 Billion | $762.63 |
| #543 | Argen-X | BR:ARGX | $49.55 Billion | €745.00 |
| #563 | UCB SA | BR:UCB | $47.34 Billion | €222.90 |
XBiotech Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, XBiotech Inc's market cap moved from $285.55 Million to $ 67.99 Million, with a yearly change of -14.52%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $67.99 Million | -6.69% |
| 2025 | $72.87 Million | -39.49% |
| 2024 | $120.43 Million | -1.25% |
| 2023 | $121.95 Million | +13.96% |
| 2022 | $107.01 Million | -68.46% |
| 2021 | $339.33 Million | -17.46% |
| 2020 | $411.12 Million | -16.15% |
| 2019 | $490.33 Million | +267.42% |
| 2018 | $133.45 Million | +28.93% |
| 2017 | $103.50 Million | -61.07% |
| 2016 | $265.85 Million | -6.90% |
| 2015 | $285.55 Million | -- |
End of Day Market Cap According to Different Sources
On Aug 3rd, 2026 the market cap of XBiotech Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $67.99 Million USD |
| MoneyControl | $67.99 Million USD |
| MarketWatch | $67.99 Million USD |
| marketcap.company | $67.99 Million USD |
| Reuters | $67.99 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About XBiotech Inc
XBiotech Inc., a biopharmaceutical company, discovers, and develops, True Human monoclonal antibodies for treating various diseases. It develops a pipeline of product candidates targeting inflammatory and infectious diseases. The company is also developing interleukin-1 alpha therapies to various medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown… Read more